The breast is positioned on the superficial fascia, resting on top of the pectoralis major muscle (2/3) and the serratus anterior muscle (1/3). The pectoralis minor muscle is located beneath the pectoralis major muscle, while the deltoid muscle forms the sleek shoulder. Therefore, neither of these muscles come into contact with the breast. The subclavius muscle is situated between the clavicle and the first rib and also does not touch the breast.

The breast is situated on a layer of pectoral fascia and is surrounded by the pectoralis major, serratus anterior, and external oblique muscles. The nerve supply to the breast comes from branches of intercostal nerves from T4-T6, while the arterial supply comes from the internal mammary (thoracic) artery, external mammary artery (laterally), anterior intercostal arteries, and thoraco-acromial artery. The breast’s venous drainage is through a superficial venous plexus to subclavian, axillary, and intercostal veins. Lymphatic drainage occurs through the axillary nodes, internal mammary chain, and other lymphatic sites such as deep cervical and supraclavicular fossa (later in disease).

The preparation for lactation involves the hormones oestrogen, progesterone, and human placental lactogen. Oestrogen promotes duct development in high concentrations, while high levels of progesterone stimulate the formation of lobules. Human placental lactogen prepares the mammary glands for lactation. The two hormones involved in stimulating lactation are prolactin and oxytocin. Prolactin causes milk secretion, while oxytocin causes contraction of the myoepithelial cells surrounding the mammary alveoli to result in milk ejection from the breast. Suckling of the baby stimulates the mechanoreceptors in the nipple, resulting in the release of both prolactin and oxytocin from the pituitary gland (anterior and posterior parts respectively).

The external oblique aponeurosis provides the outermost layer of the spermatic cord, which is acquired during its passage through the superficial inguinal ring.

Anatomy of the Scrotum and Testes

The scrotum is composed of skin and dartos fascia, with an arterial supply from the anterior and posterior scrotal arteries. It is also the site of lymphatic drainage to the inguinal lymph nodes. The testes are surrounded by the tunica vaginalis, a closed peritoneal sac, with the parietal layer adjacent to the internal spermatic fascia. The testicular arteries arise from the aorta, just below the renal arteries, and the pampiniform plexus drains into the testicular veins. The left testicular vein drains into the left renal vein, while the right testicular vein drains into the inferior vena cava. Lymphatic drainage occurs to the para-aortic nodes.

The spermatic cord is formed by the vas deferens and is covered by the internal spermatic fascia, cremasteric fascia, and external spermatic fascia. The cord contains the vas deferens, testicular artery, artery of vas deferens, cremasteric artery, pampiniform plexus, sympathetic nerve fibers, genital branch of the genitofemoral nerve, and lymphatic vessels. The vas deferens transmits sperm and accessory gland secretions, while the testicular artery supplies the testis and epididymis. The cremasteric artery arises from the inferior epigastric artery, and the pampiniform plexus is a venous plexus that drains into the right or left testicular vein. The sympathetic nerve fibers lie on the arteries, while the parasympathetic fibers lie on the vas. The genital branch of the genitofemoral nerve supplies the cremaster. Lymphatic vessels drain to lumbar and para-aortic nodes.

The use of HRT is associated with a higher likelihood of thrombotic events, including stroke. This is due to platelet aggregation, which is distinct from the accumulation of cholesterol that primarily contributes to atheroma formation. HRT does not elevate the risk of thrombocytopaenia or vulval cancer, and the inclusion of progesterone in the HRT helps to reduce the risk of developing endometrial cancer.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It typically occurs when a woman reaches the age of 51 in the UK. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

An ectopic pregnancy is likely in this case, as the symptoms suggest a diagnosis of pelvic inflammatory disease. This condition can cause scarring and damage to the Fallopian tubes, which can impede the fertilized egg’s passage to the uterus, resulting in an ectopic pregnancy.

The combined oral contraceptive pill is not a well-documented risk factor for ectopic pregnancy, but the progesterone-only pill and intrauterine contraceptive device are. Both IVF and subfertility are also risk factors for ectopic pregnancies, while smoking or exposure to cigarette smoke increases the risk.

Understanding Ectopic Pregnancy: Incidence and Risk Factors

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus, usually in the fallopian tubes. This condition is a serious medical emergency that requires immediate attention. According to epidemiological studies, ectopic pregnancy occurs in approximately 0.5% of all pregnancies.

Several risk factors can increase the likelihood of ectopic pregnancy. These include damage to the fallopian tubes due to pelvic inflammatory disease or surgery, a history of previous ectopic pregnancy, endometriosis, the use of intrauterine contraceptive devices (IUCDs), and the progesterone-only pill. In vitro fertilization (IVF) also increases the risk of ectopic pregnancy, with approximately 3% of IVF pregnancies resulting in ectopic implantation.

It is important for women to be aware of the risk factors associated with ectopic pregnancy and to seek medical attention immediately if they experience symptoms such as abdominal pain, vaginal bleeding, or shoulder pain. Early diagnosis and treatment can help prevent serious complications and improve outcomes for both the mother and the fetus.

The combined oral contraceptive pill has been found to have a slightly higher risk of breast cancer, but it is protective against ovarian and endometrial cancer. Women with known breast cancer mutations like BRCA1 should avoid taking the pill as the risk may outweigh the benefits. Additionally, women with current breast cancer should not take the pill. After 5 years of use, there is a small increase in cervical cancer risk, which doubles after 10 years. However, cervical cancer is not a reason to avoid using the pill.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

The presence of ↑ HCG, ↓ PAPP-A, and a thickened nuchal translucency is indicative of Down’s syndrome. The combined screening test, which includes an ultrasound scan and blood test, is used to assess the risk of the fetus having Down’s syndrome, Edwards’ syndrome, and Patau’s syndrome. However, a diagnostic test such as amniocentesis or chorionic villus sampling is required to confirm the diagnosis. Advanced maternal age is also a significant risk factor for Down’s syndrome. The answer choices ‘↑ HCG, ↑ PAPP-A, increased amount of nuchal fluid’, ‘↑ HCG, ↓ PAPP-A, normal amount of nuchal fluid’, and ‘↓ HCG, ↓ PAPP-A, decreased amount of nuchal fluid’ are incorrect as they do not match the typical indicators of Down’s syndrome.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The quadruple test should be offered between 15-20 weeks for women who book later in pregnancy. Results of both tests return either a ‘lower chance’ or ‘higher chance’ result. If a woman receives a ‘higher chance’ result, she will be offered a second screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA from placental cells in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities, with private companies offering screening from 10 weeks gestation.

PPH, which is the loss of 500 millilitres or more of blood within 24 hours of delivery, is primarily caused by uterine atony. This occurs when the uterus fails to contract after the placenta is delivered. However, other potential causes must be ruled out through thorough clinical examination. To remember the causes of PPH, the acronym ‘the 4 Ts’ can be used: Tone (uterine atony), Tissue (retained products of conception), Trauma (to the genital tract or perineum), and Thrombin (coagulation abnormalities). This information is based on RCOG Green-top Guideline No. 52.

Postpartum Haemorrhage: Causes, Risk Factors, and Management

Postpartum haemorrhage (PPH) is a condition characterized by excessive blood loss of more than 500 ml after a vaginal delivery. It can be primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia. Management of PPH is a life-threatening emergency that requires immediate involvement of senior staff. The ABC approach is used, and bloods are taken, including group and save. Medical management includes IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options are considered if medical management fails to control the bleeding. Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage is a serious condition that can occur after vaginal delivery. It is important to understand the causes, risk factors, and management of this condition to ensure prompt and effective treatment. Primary PPH is caused by the 4 Ts, with uterine atony being the most common cause. Risk factors for primary PPH include previous PPH, prolonged labour, and emergency Caesarean section. Management of PPH is a life-threatening emergency that requires immediate involvement of senior staff. Medical management includes IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options are considered if medical management fails to control the bleeding. Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to be aware of the signs and symptoms of PPH and seek medical attention immediately if they occur.

During menopause, there is a decrease in oestrogen levels due to the ovaries responding poorly to FSH and LH. This leads to an increase in both FSH and LH levels as there is less negative feedback from oestrogen. Therefore, any response indicating high levels of one hormone and low levels of the other is incorrect.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It typically occurs when a woman reaches the age of 51 in the UK. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

During the early stages of pregnancy, the corpus luteum is stimulated to secrete progesterone by hCG, which is produced by the syncytiotrophoblast. Pregnancy tests commonly measure hCG levels in urine. This hormone is crucial for maintaining the pregnancy until the placenta is fully developed. The trophoblast is composed of two layers: the cytotrophoblast and the syncytiotrophoblast. The hypoblast is a type of tissue that forms from the inner cell mass, while the epiblast gives rise to the three primary germ layers and extraembryonic mesoderm.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

The woman has HELLP syndrome, a severe form of pre-eclampsia. Management includes magnesium sulfate, dexamethasone, blood pressure control, and blood product replacement. Delivery of the fetus is the only cure.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, age over 40, high BMI, family history of pre-eclampsia, and multiple pregnancy. To reduce the risk of hypertensive disorders in pregnancy, women with high or moderate risk factors should take aspirin daily. Management involves emergency assessment, admission for severe cases, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

The production of testosterone in response to LH is carried out by Leydig cells, not Sertoli cells in the testes.

Leydig cells are responsible for the secretion of testosterone when LH is released from the anterior pituitary gland. On the other hand, Sertoli cells are referred to as nurse cells because they provide nourishment to developing sperm during spermatogenesis. These cells have an elongated shape, secrete androgen-binding protein and tubular fluid, support the development of sperm during spermatogenesis, and form the blood-testes barrier.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

The symptoms and indications described indicate that the patient is suffering from severe pre-eclampsia. It should be noted that not all antihypertensive drugs are safe for use during pregnancy due to their teratogenic effects. Therefore, hydrocortisone is the only drug mentioned that is not an antihypertensive. Among the antihypertensive drugs mentioned, labetalol is the most suitable option as it is recommended as a first-line drug for managing severe hypertension in pregnant patients according to NICE guidelines.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, pre-term birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Smoking is a protective factor against only one type of cancer, which is endometrial cancer (3), as found by a meta-analysis. However, smoking is a risk factor for all the other types of cancer mentioned.

For bladder cancer (1), it is suggested that the aromatic amines found in cigarettes are a known carcinogen of the bladder, thus contributing to the increased risk of bladder cancer with smoking.

Although smoking is a well-established co-factor for the development of cervical cancer (2), the mechanism by which smoking increases the risk is not known, although there are two theories.

Smoking has been found to cause numerous DNA changes in laryngeal cancer (4), including TP53 gene mutations.

Smoking is also theorized to cause renal cell cancer (5) as cigarette smoke induces oxidative stress and injury in the kidney, and free radicals in cigarettes can cause DNA damage that may lead to the development of cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Symptoms of endometrial cancer include postmenopausal bleeding, which is usually slight and intermittent at first before becoming heavier, and changes in intermenstrual bleeding for premenopausal women. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness of less than 4 mm. Hysteroscopy with endometrial biopsy is also commonly used for diagnosis. Treatment for localized disease typically involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may require postoperative radiotherapy. Progestogen therapy may be used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

The Onufs nucleus, which is responsible for providing neurons to the external urethral sphincter, is located in the anterior horn of S2. In females, the sphincter complex at the bladder neck is not well-developed, making the external sphincter complex more important. It is innervated by the pudendal nerve, and damage to this nerve due to obstetric events can lead to stress urinary incontinence. The bladder is innervated by the pudendal, hypogastric, and pelvic nerves, which also carry autonomic nerves. Sympathetic nerves cause detrusor relaxation and sphincter contraction during bladder filling, while parasympathetic nerves cause detrusor contraction and sphincter relaxation. The Pons is responsible for centrally mediating control of micturition.

Urinary incontinence is a common condition that affects approximately 4-5% of the population, with elderly females being more susceptible. There are several risk factors that can contribute to the development of urinary incontinence, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. The condition can be classified into different types, such as overactive bladder, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of urinary incontinence involves completing bladder diaries for at least three days, performing a vaginal examination to exclude pelvic organ prolapse, and conducting urine dipstick and culture tests. Urodynamic studies may also be necessary. Management of urinary incontinence depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures may be necessary. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be offered to women who decline surgical procedures.

In summary, urinary incontinence is a common condition that can be caused by various risk factors. It can be classified into different types, and management depends on the predominant type of incontinence. Initial investigation involves completing bladder diaries, performing a vaginal examination, and conducting urine tests. Treatment options include bladder retraining, bladder stabilizing drugs, pelvic floor muscle training, surgical procedures, and duloxetine.

Miscarriage is the loss of a pregnancy before the 20th week. It is a common occurrence, with about 10-20% of pregnancies ending in miscarriage. In most cases, the cause of miscarriage is unknown, but it can be due to genetic abnormalities, hormonal imbalances, or health conditions such as diabetes or thyroid problems.

There are different types of miscarriage, including complete, incomplete, inevitable, and septic. A complete miscarriage is when all fetal tissue has been passed, bleeding has stopped, the uterus is no longer enlarged, and the cervical os is closed. An incomplete miscarriage is when only some fetal parts have been passed, and the cervical os is usually open. An inevitable miscarriage means that a miscarriage is about to occur, with the fetus still possibly alive but the cervical os open and bleeding usually heavier. A septic miscarriage occurs when the contents of the uterus are infected, causing endometritis. Symptoms include offensive vaginal loss, tender uterus, and in cases of pelvic infection, abdominal pain and peritonism.

Types of Miscarriage

Miscarriage is a common complication that can occur during pregnancy. There are different types of miscarriage, each with its own set of symptoms and characteristics. One type is threatened miscarriage, which is painless vaginal bleeding that occurs before 24 weeks, typically at 6-9 weeks. The bleeding is usually less than menstruation, and the cervical os is closed. This type of miscarriage complicates up to 25% of all pregnancies.

Another type is missed (delayed) miscarriage, which is characterized by a gestational sac that contains a dead fetus before 20 weeks without the symptoms of expulsion. The mother may experience light vaginal bleeding or discharge and the disappearance of pregnancy symptoms, but pain is not usually present. The cervical os is closed, and when the gestational sac is larger than 25 mm and no embryonic or fetal part can be seen, it is sometimes referred to as a blighted ovum or anembryonic pregnancy.

Inevitable miscarriage is another type, which is characterized by heavy bleeding with clots and pain. The cervical os is open in this case. Lastly, incomplete miscarriage occurs when not all products of conception have been expelled. This type of miscarriage is characterized by pain and vaginal bleeding, and the cervical os is open. Understanding the different types of miscarriage can help individuals recognize the symptoms and seek appropriate medical attention.

HIV and Pregnancy: Guidelines for Minimizing Vertical Transmission

With the increasing prevalence of HIV infection among heterosexual individuals, there has been a rise in the number of HIV-positive women giving birth in the UK. In London, the incidence may be as high as 0.4% of pregnant women. The goal of treating HIV-positive women during pregnancy is to minimize harm to both the mother and fetus and to reduce the chance of vertical transmission.

To achieve this goal, various factors must be considered. Guidelines on this subject are regularly updated, and the most recent guidelines can be found using the links provided. Factors that can reduce vertical transmission from 25-30% to 2% include maternal antiretroviral therapy, mode of delivery (caesarean section), neonatal antiretroviral therapy, and infant feeding (bottle feeding).

To ensure that HIV-positive women receive appropriate care during pregnancy, NICE guidelines recommend offering HIV screening to all pregnant women. Additionally, all pregnant women should be offered antiretroviral therapy, regardless of whether they were taking it previously.

The mode of delivery is also an important consideration. Vaginal delivery is recommended if the viral load is less than 50 copies/ml at 36 weeks. Otherwise, a caesarean section is recommended, and a zidovudine infusion should be started four hours before beginning the procedure.

Neonatal antiretroviral therapy is also crucial in minimizing vertical transmission. Zidovudine is usually administered orally to the neonate if the maternal viral load is less than 50 copies/ml. Otherwise, triple ART should be used, and therapy should be continued for 4-6 weeks.

Finally, infant feeding is another important factor to consider. In the UK, all women should be advised not to breastfeed to minimize the risk of vertical transmission. By following these guidelines, healthcare providers can help minimize the risk of vertical transmission and ensure that HIV-positive women receive appropriate care during pregnancy.

It is important to be aware of the role that hormones play during pregnancy.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

Following ovulation, the body temperature increases, which can be used as a method of behavioural contraception. By measuring and plotting the temperature each day, patients can identify their fertile window and use alternative contraception during this time. However, this method is less effective than hormonal contraception. The rise in temperature is due to the increase in progesterone levels, which is maintained after fertilisation. The initiation of the follicular phase and menses do not cause a rapid rise in temperature, as the progesterone levels are typically low during these phases. A peak in oestrogen does not affect the body temperature.

Phases of the Menstrual Cycle

The menstrual cycle is a complex process that can be divided into four phases: menstruation, follicular phase, ovulation, and luteal phase. During the follicular phase, a number of follicles develop in the ovaries, with one follicle becoming dominant around the mid-follicular phase. At the same time, the endometrium undergoes proliferation. This phase is characterized by a rise in follicle-stimulating hormone (FSH), which results in the development of follicles that secrete oestradiol. When the egg has matured, it secretes enough oestradiol to trigger the acute release of luteinizing hormone (LH), which leads to ovulation.

During the luteal phase, the corpus luteum secretes progesterone, which causes the endometrium to change to a secretory lining. If fertilization does not occur, the corpus luteum will degenerate, and progesterone levels will fall. Oestradiol levels also rise again during the luteal phase. Cervical mucus thickens and forms a plug across the external os following menstruation. Just prior to ovulation, the mucus becomes clear, acellular, low viscosity, and stretchy. Under the influence of progesterone, it becomes thick, scant, and tacky. Basal body temperature falls prior to ovulation due to the influence of oestradiol and rises following ovulation in response to higher progesterone levels. Understanding the phases of the menstrual cycle is important for women’s health and fertility.

During pregnancy, the placenta produces beta-hCG, which helps to sustain the corpus luteum. This, in turn, continues to secrete progesterone and estrogen throughout the pregnancy to maintain the endometrial lining. Eventually, after 6 weeks of gestation, the placenta takes over the production of progesterone.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

Women with migraine who use combined contraception have a higher risk of stroke. A transient ischemic attack (TIA) is a sign that a stroke may occur. The risk of stroke for women with migraine using combined contraception is 8 per 100,000 at age 20 and increases to 40 per 100,000 at age 40.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than one per 100 woman years. It is a convenient option that does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to consider. One of the main drawbacks is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections, so additional precautions may be necessary. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side effects such as headache, nausea, and breast tenderness may also be experienced.

Despite some reports of weight gain, a Cochrane review did not find a causal relationship between the combined oral contraceptive pill and weight gain. Overall, the combined oral contraceptive pill can be a safe and effective option for birth control, but it is important to weigh the pros and cons and discuss any concerns with a healthcare provider.

Pregnant women should discontinue the use of ACE inhibitors like ramipril or AIIRA like losartan as they have been linked to negative fetal outcomes. Labetalol is typically the preferred medication for managing hypertension during pregnancy, unless there are medical reasons not to use it.

Hypertension during pregnancy is a common condition that can be managed effectively with proper care. In normal pregnancy, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, if a pregnant woman develops hypertension, it is usually defined as a systolic blood pressure of over 140 mmHg or a diastolic blood pressure of over 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from booking readings can also indicate hypertension.

After confirming hypertension, the patient should be categorized into one of three groups: pre-existing hypertension, pregnancy-induced hypertension (PIH), or pre-eclampsia. PIH, also known as gestational hypertension, occurs in 3-5% of pregnancies and is more common in older women. If a pregnant woman takes an ACE inhibitor or angiotensin II receptor blocker for pre-existing hypertension, it should be stopped immediately, and alternative antihypertensives should be started while awaiting specialist review.

Pregnancy-induced hypertension in association with proteinuria, which occurs in around 5% of pregnancies, may also cause oedema. The 2010 NICE guidelines recommend oral labetalol as the first-line treatment for hypertension during pregnancy. Oral nifedipine and hydralazine may also be used, depending on the patient’s medical history. It is important to manage hypertension during pregnancy effectively to reduce the risk of complications and ensure the health of both the mother and the baby.

The likely cause of this patient’s amenorrhoea and galactorrhoea is a prolactinoma, which inhibits the secretion of GnRH and leads to low levels of oestrogen. Further tests, including a urinary pregnancy test and blood tests for various hormones, should be conducted to confirm the diagnosis. Asherman’s syndrome, intraductal papilloma, and pregnancy are less likely causes, as they do not present with the same symptoms or do not fit the patient’s reported history.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

During pregnancy, women are checked for anaemia twice – once at the initial booking visit (usually at 8-10 weeks) and again at 28 weeks. The National Institute for Health and Care Excellence (NICE) has set specific cut-off levels to determine if a woman requires oral iron therapy. For the first trimester, the cut-off is less than 110 g/L, for the second and third trimesters, it is less than 105 g/L, and for the postpartum period, it is less than 100 g/L. If a woman falls below these levels, she should receive oral ferrous sulfate or ferrous fumarate. Treatment should continue for three months after iron deficiency is corrected to allow for the replenishment of iron stores.

Anastrozole and letrozole are medications that belong to the class of drugs known as aromatase inhibitors. These drugs are commonly used in the treatment of breast cancer as they work by reducing the production of oestrogen in the body. Aromatase is an enzyme that converts androgens into oestrogens, and these drugs inhibit this process, which typically occurs in adipose tissue.

Tamoxifen is another medication used in the treatment of breast cancer. It works by blocking oestrogen receptors in breast tissue, which reduces the growth of breast cancer cells. However, tamoxifen can activate oestrogen receptors in other parts of the body, which increases the risk of endometrial cancer.

GnRH analogues, such as goserelin, are used in the treatment of various types of cancer, including breast and prostate cancer. These drugs work by inhibiting the secretion of gonadotropins from the pituitary gland, which reduces the stimulation of the ovaries.

Trastuzumab, also known as Herceptin, is a monoclonal antibody that is used to treat HER2-positive breast cancer. This drug works by binding to HER2 receptors, which are overexpressed in some breast cancer cells, and inhibiting their growth.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flushes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flushes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

Phenytoin is a well-established cause of folic acid deficiency, along with excess alcohol, methotrexate, and pregnancy. Menopause is not typically associated with folate deficiency, but rather a deficiency in vitamin B12. Smoking tobacco and laxative abuse are not known to cause folate deficiency. It is important to note that vitamin B12 and folic acid are linked in megaloblastic anemia, but administering vitamin B12 injections does not cause folate deficiency. Additionally, it is crucial to correct low vitamin B12 levels before supplementing with folate to avoid subacute combined degeneration of the spinal cord.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. THF plays a crucial role in transferring 1-carbon units to essential substrates involved in DNA and RNA synthesis. Green, leafy vegetables are a good source of folic acid. However, certain medications like phenytoin and methotrexate, pregnancy, and alcohol excess can cause folic acid deficiency. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, all women should take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5 mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if either partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with antiepileptic drugs or coeliac disease, diabetes, or thalassaemia trait, and those who are obese (BMI of 30 kg/m2 or more) are also at higher risk and should take the higher dose of folic acid.

Rh disease is commonly linked with hydrops fetalis, a form of Haemolytic Disease of the Newborn. While Kernicterus is a possible outcome of Rh disease, it is not accurate to associate it with hepato-splenomegaly. Haemolysis leads to bilirubinemia, which is highly toxic to the nervous system, but it does not cause an enlargement of the liver and spleen. Although foetal heart failure can cause hepatomegaly, it is not related to Rh disease. Foetal liver failure, which may cause hepatomegaly, does not necessarily result in splenomegaly and is not associated with Rh disease.

Rhesus negative mothers can develop anti-D IgG antibodies if they deliver a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis at 28 and 34 weeks. Anti-D should also be given in various situations, such as delivery of a Rh +ve infant or amniocentesis. Tests include cord blood FBC, blood group, direct Coombs test, and Kleihauer test. Affected fetuses may experience oedema, jaundice, anaemia, hepatosplenomegaly, heart failure, and kernicterus, and may require transfusions and UV phototherapy.

Smoking while pregnant is associated with a higher likelihood of having a baby that is small for gestational age. The increased risk is thought to be due to exposure to nicotine and carbon monoxide. Diabetes mellitus, previous pregnancy, and maternal obesity are not linked to small for gestational age babies, but rather to large for gestational age babies.

Small for Gestational Age (SGA) is a statistical definition used to describe babies who are smaller than expected for their gestational age. Although there is no universally agreed percentile, the 10th percentile is often used, meaning that 10% of normal babies will be below this threshold. SGA can be determined either antenatally or postnatally. There are two types of SGA: symmetrical and asymmetrical. Symmetrical SGA occurs when the fetal head circumference and abdominal circumference are equally small, while asymmetrical SGA occurs when the abdominal circumference slows relative to the increase in head circumference.

There are various causes of SGA, including incorrect dating, constitutionally small (normal) babies, and abnormal fetuses. Symmetrical SGA is more common and can be caused by idiopathic factors, race, sex, placental insufficiency, pre-eclampsia, chromosomal and congenital abnormalities, toxins such as smoking and heroin, and infections such as CMV, parvovirus, rubella, syphilis, and toxoplasmosis. Asymmetrical SGA is less common and can be caused by toxins such as alcohol, cigarettes, and heroin, chromosomal and congenital abnormalities, and infections.

The management of SGA depends on the type and cause. For symmetrical SGA, most cases represent the lower limits of the normal range and require fortnightly ultrasound growth assessments to demonstrate normal growth rates. Pathological causes should be ruled out by checking maternal blood for infections and searching the fetus carefully with ultrasound for markers of chromosomal abnormality. Asymmetrical SGA also requires fortnightly ultrasound growth assessments, as well as biophysical profiles and Doppler waveforms from umbilical circulation to look for absent end-diastolic flow. If results are sub-optimal, delivery may be considered.

Macrosomia is a significant risk factor for neonatal brachial plexus injuries resulting from shoulder dystocia. Maternal diabetes mellitus, not diabetes insipidus, is the leading cause of macrosomia, which is often associated with a high BMI. While polyhydramnios may result from foetal insulin resistance due to maternal diabetes mellitus, it is not a specific risk factor for brachial plexus injuries as there are many other causes of polyhydramnios. A family history of preeclampsia is not relevant to this condition.

Shoulder dystocia is a complication that can occur during vaginal delivery when the body of the fetus cannot be delivered after the head has already been delivered. This is usually due to the anterior shoulder of the fetus becoming stuck on the mother’s pubic bone. Shoulder dystocia can cause harm to both the mother and the baby.

There are several risk factors that increase the likelihood of shoulder dystocia, including fetal macrosomia (large baby), high maternal body mass index, diabetes mellitus, and prolonged labor.

If shoulder dystocia is identified, it is important to call for senior medical assistance immediately. The McRoberts’ maneuver is often used to help deliver the baby. This involves flexing and abducting the mother’s hips to increase the angle of the pelvis and facilitate delivery. An episiotomy may be performed to provide better access for internal maneuvers, but it will not relieve the bony obstruction. Symphysiotomy and the Zavanelli maneuver are not recommended as they can cause significant harm to the mother. Oxytocin administration is not effective in treating shoulder dystocia.

Complications of shoulder dystocia can include postpartum hemorrhage and perineal tears for the mother, and brachial plexus injury or neonatal death for the baby. It is important to manage shoulder dystocia promptly and effectively to minimize these risks.

The patient’s medical history suggests pre-eclampsia, which is characterized by high blood pressure and protein in the urine after 20 weeks of pregnancy. antihypertensive medication should be used to manage blood pressure. Women with this condition may also develop HELLP syndrome, which is characterized by low platelets, elevated liver enzymes, and haemolysis (indicated by raised LDH levels). If left untreated, pre-eclampsia can progress to eclampsia, which can be prevented by administering magnesium sulphate. Delivery is the only definitive treatment for pre-eclampsia.

Symptoms of shock include tachycardia and hypotension, while Cushing’s triad (bradycardia, hypertension, and respiratory irregularity) is indicative of raised intracranial pressure. Anaphylaxis is characterized by facial swelling, rash, and stridor, while sepsis may present with warm extremities, rigors, and a strong pulse.

Jaundice During Pregnancy

During pregnancy, jaundice can occur due to various reasons. One of the most common liver diseases during pregnancy is intrahepatic cholestasis of pregnancy, which affects around 1% of pregnancies and is usually seen in the third trimester. Symptoms include itching, especially in the palms and soles, and raised bilirubin levels. Ursodeoxycholic acid is used for symptomatic relief, and women are typically induced at 37 weeks. However, this condition can increase the risk of stillbirth.

Acute fatty liver of pregnancy is a rare complication that can occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea, vomiting, headache, jaundice, and hypoglycemia. ALT levels are typically elevated. Supportive care is the initial management, and delivery is the definitive management once the patient is stabilized.

Gilbert’s and Dubin-Johnson syndrome may also be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for Haemolysis, Elevated Liver enzymes, Low Platelets, can also cause jaundice during pregnancy. It is important to monitor liver function tests and seek medical attention if any symptoms of jaundice occur during pregnancy.